apuestas deportivas bet365
ROCKVILLE, Md. , Dec. 17, 2024 /PRNewswire/ -- StarCompliance (Star), a leading SaaS provider of employee compliance technology solutions, today announced the recipients of its Star Client Awards. The awards, which celebrate innovation, collaboration, and culture in regtech, recognized four clients in EMEA, seven in North America , and two in APAC. Star will be donating $1,000 to each winner's charity of choice. "It's a privilege to extend my congratulations to all recipients of the Star Client Awards, honoring innovation, collaboration, and culture, especially as we celebrate Star's 25th anniversary," said Star's CEO, Jennifer Sun . "Over the past quarter century, our collaboration with clients has been vital, enabling us to continuously enhance our platform. Their invaluable feedback guides our allocation of time, resources, and efforts, ensuring that our technology remains impactful in the ever-evolving compliance sector." The Star Innovator Awards were presented to multiple clients including California Pizza Kitchen , in recognition of their outstanding adoption and integration of novel technologies. These companies showcased unique processes to address specific business challenges over the past year, whether through the STAR Platform or other means. ANZ Banking Group, C erberus Capital Management , MFS Investment Management , and NatWest were honored with the Star Collaborator Award for their dedication and contributions over the past year, as their teams collaborated with Star. Their support played a significant role in advancing and innovating the STAR Platform. The Star Influencer Awards recognized Baillie Gifford and ICapital for their initiatives in integrating compliance into their core business DNA. Their endeavors have positively shaped and enhanced their organizations' view on compliance. The Rising Star Awards celebrated Advent International , Brightwell and Mercer as exceptional organizations who have created an outstanding impact within Star's client community. About StarCompliance StarCompliance is the world's leading provider of employee compliance technology solutions. Trusted for over 25 years by more than one million users in 114 countries, Star's next-generation platform and user-friendly interface delivers the data, technology, and actionable insights needed to proactively mitigate risk, monitor conflicts globally, and support complex whistleblowing regulations. Visit www.starcompliance.com to discover the comprehensive security and unparalleled assurance you need to build a culture of compliance today. This is not an endorsement by any company referenced herein of StarCompliance, or StarCompliance's products or services. Media Contact: [email protected] +1 917-868-7791 Logo - https://mma.prnasia.com/media2/2582873/Star_Compliance_Logo.jpg?p=medium600
Adrian Butler Elected to PRA Group Board of Directors
QND represents the pride in prudent leadership’s policies that helped build profound economic base: QCB governorSamsung Galaxy S25 Ultra: Leaked Features and Tipped Upgrades
What if we told you that is now as simple as piecing together a LEGO set? These new DIY kits will make you feel like a mix of your inner child and a genius as you create what looks like a vintage Gameboy and learn to program your own games. When you buy this CircuitMess kit, you’ll get another one to build a retro-style walkie-talkie. Suitable for ages 11 and up, this bundle is a great way to treat yourself and check off a holiday gift. while supplies last—we only have 40 in stock. Gifting either as a gift and joining them in the fun could spark kids’ interest in science, technology, engineering, or coding. Imagine being the fun uncle or aunt who ends up being the reason they work for NASA or Blue Origin. Don’t just be a gamer—understand how games came to be. You don’t need any prior knowledge or tools; everything is included in the kit. You’ll learn how to build the gaming console using a soldering station and screwdrivers to connect the standoffs and cases. Then, you can with help from a step-by-step guide. If that’s not your style, there are also preloaded retro games to play out of the box. Kids might enjoy this kit more, especially after the interactive assembly. They can send text messages back and forth without internet or cellular networks, teaching them about long-range wireless communication. Get the for $199 with free shipping before we sell out—less than 40 are left in stock.QND represents the pride in prudent leadership’s policies that helped build profound economic base: QCB governor
HUMBOLDT, Tenn. (AP) — A Tennessee man was convicted Thursday of killing two men and wounding a third in a shooting at a high school basketball game three years ago. Jadon Hardiman, 21, was found guilty in Gibson County of charges including second-degree murder, attempted murder, aggravated assault and weapons offenses, district attorney Frederick Agee said in a statement. He faces up to 76 years in prison at sentencing in April. Hardiman, of Jackson, attended a basketball game between Humboldt and North Side high schools on Nov. 30, 2021. Then 18, Hardiman entered the Humboldt gymnasium's crowded concession area and pulled a semi-automatic .40 caliber handgun, prosecutors said. He fired three shots at Justin Pankey, a 21-year-old former Humboldt basketball player. Pankey was hit one time and died within seconds, Agee said. A second bullet hit Xavier Clifton, a former North Side student and basketball player, who was standing in the concession line. Clifton was shot in the neck and paralyzed. He died in March 2022. A third shot struck another man in the back of the head. He survived. “Many people were placed in fear of imminent bodily injury by Hardiman’s shooting, as shown by video footage of their fleeing into the gym, into bathrooms, and other areas of the school,” Agee said. Hardiman ran away and drove to Jackson, disposing of the murder weapon along the way, the district attorney said. The U.S. Marshals Service contacted his family, and he was arrested the next day. Agee said the shooting "frightened every adult, student, and child present, who were only there to support their team and enjoy a good game.” Hardiman's lawyer did not immediately return a call seeking comment.Researchers from the National Institutes of Health are using large language models to develop an artificial intelligence framework to streamline the clinical trial matching process and more quickly link potential volunteers to relevant trials listed on ClinicalTrials.gov. Benchmarking its accuracy against three human clinicians, researchers have found that the tool, TrialGPT, achieved nearly the same level of accuracy, according to an NIH announcement this month. WHY IT MATTERS Because finding the right clinical trial for a patient is both time and resource-intensive, researchers at the National Library of Medicine and National Cancer Institute developed the TrialGPT framework to streamline it. The new clinical trial matching algorithm analyzes patient summaries for relevant medical and demographic information then identifies clinical trials for which a patient is eligible and excludes trials for which they are not. TrialGPT produces an annotated list of clinical trials – ranked by relevance and eligibility – that clinicians can use to discuss clinical trial opportunities with their patients. The AI tool also explains how a person meets the study enrollment criteria, which is critical to its efficacy. To assess how well TrialGPT predicted if a patient met a specific requirement for a clinical trial, the researchers compared the tool's results to those of three human clinicians who assessed more than 1,000 patient-criterion pairs, NIH said. "Machine learning and AI technology have held promise in matching patients with clinical trials, but their practical application across diverse populations still needed exploration," Stephen Sherry, NLM's acting director, said in a statement. The researchers also conducted a pilot user study and found that when clinicians used TrialGPT, they spent 40% less time screening patients but maintained the same level of accuracy. Of note, TrialGPT relies on OpenAI’s GPT series LLMs such as GPT-3.5 and GPT-4 and the latter is closed-source and can only be accessed via commercial applications or API, the researchers said in their report . For their study, published in Nature Communications and co-authored by collaborators from Albert Einstein College of Medicine, University of Pittsburgh, University of Illinois Urbana-Champaign and University of Maryland, College Park, the research team received an innovation award and will further assess the model’s performance and fairness in real-world clinical settings, NIH said. THE LARGER TREND Using AI to improve patient recruitment, retention and outcomes of clinical trials began before OpenAI launched its ChatGPT generative AI model. During the COVID-19 pandemic, oncology organizations sought ways to find patients across the country who would qualify for trials, even if they weren't physically there, through healthcare data. In driving decentralized clinical trials , increased AI adoption helped to advance health equity and trial diversity, according to Jeff Elton, CEO of ConcertAI, a vendor of data and AI SaaS platforms for clinical trial optimization. "With integrated digital trials, clinical studies are integral to the care process itself, versus being imposed on it," Elton told Healthcare IT News . "Trials don't need to place a higher burden on providers and patients than the standard of care." Reducing friction throughout the clinical trial lifecycle is critical to helping patients access trial therapies, according to Seth Howard, vice president of research and development at Epic. The electronic health record vendor implemented data-driven clinical trial matchmaking two years ago. Using its de-identified Cosmos data set, Epic allows providers that register for the service to match clinical trial opportunities from sponsors and a count of their organization’s eligible patients. Many health systems have also tested using analytical applications that can surface clinical trial opportunities for patients using their organizations' EHR data. In October, Microsoft announced new AI tools that will enable health systems to build their custom AI tools for many administrative needs – including clinical trial matching. Bias in AI, however, is still a concern for clinical outcomes. It can surface in any algorithm development pipeline and worsen healthcare disparities , Yale School of Medicine researchers said in new research published earlier this month. ON THE RECORD "Our study shows that TrialGPT could help clinicians connect their patients to clinical trial opportunities more efficiently and save precious time that can be better spent on harder tasks that require human expertise," Zhiyong Lu, NLM senior investigator and the study's corresponding author, said in a statement. "This study shows we can responsibly leverage AI technology so physicians can connect their patients to a relevant clinical trial that may be of interest to them with even more speed and efficiency," Sherry added. Andrea Fox is senior editor of Healthcare IT News. Email: afox@himss.org Healthcare IT News is a HIMSS Media publication.
Eastman Chemical ( NYSE:EMN – Get Free Report ) ‘s stock had its “sector perform” rating restated by research analysts at Royal Bank of Canada in a report released on Friday, Benzinga reports. They presently have a $105.00 price target on the basic materials company’s stock. Royal Bank of Canada’s price target would suggest a potential downside of 0.56% from the company’s current price. Several other brokerages also recently weighed in on EMN. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Eastman Chemical from $115.00 to $110.00 and set a “hold” rating for the company in a research report on Monday, November 4th. Wells Fargo & Company reduced their price target on shares of Eastman Chemical from $118.00 to $110.00 and set an “equal weight” rating for the company in a research report on Monday, November 4th. Mizuho raised their price objective on Eastman Chemical from $107.00 to $113.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. Barclays boosted their target price on Eastman Chemical from $103.00 to $111.00 and gave the company an “equal weight” rating in a report on Monday, July 29th. Finally, Bank of America downgraded Eastman Chemical from a “buy” rating to a “neutral” rating and raised their price target for the stock from $114.00 to $119.00 in a research note on Wednesday, October 16th. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Eastman Chemical has a consensus rating of “Hold” and an average price target of $111.50. Check Out Our Latest Analysis on Eastman Chemical Eastman Chemical Stock Performance Eastman Chemical ( NYSE:EMN – Get Free Report ) last released its quarterly earnings data on Thursday, October 31st. The basic materials company reported $2.26 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.12. The business had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.38 billion. Eastman Chemical had a return on equity of 15.37% and a net margin of 9.47%. The business’s revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.47 EPS. On average, sell-side analysts anticipate that Eastman Chemical will post 7.63 earnings per share for the current fiscal year. Insider Transactions at Eastman Chemical In other news, SVP Christopher Moore Killian sold 3,061 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $105.00, for a total transaction of $321,405.00. Following the completion of the transaction, the senior vice president now directly owns 12,366 shares of the company’s stock, valued at approximately $1,298,430. This represents a 19.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink . Company insiders own 1.93% of the company’s stock. Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bessemer Group Inc. boosted its position in shares of Eastman Chemical by 321.2% during the 1st quarter. Bessemer Group Inc. now owns 16,250 shares of the basic materials company’s stock worth $1,628,000 after purchasing an additional 12,392 shares in the last quarter. Dakota Wealth Management grew its position in Eastman Chemical by 13.5% during the second quarter. Dakota Wealth Management now owns 22,280 shares of the basic materials company’s stock worth $2,183,000 after buying an additional 2,655 shares during the period. KBC Group NV increased its holdings in Eastman Chemical by 21.8% in the third quarter. KBC Group NV now owns 110,610 shares of the basic materials company’s stock valued at $12,383,000 after buying an additional 19,809 shares in the last quarter. Principal Financial Group Inc. lifted its position in shares of Eastman Chemical by 6.8% during the 3rd quarter. Principal Financial Group Inc. now owns 148,176 shares of the basic materials company’s stock valued at $16,588,000 after acquiring an additional 9,447 shares during the period. Finally, Cetera Advisors LLC boosted its stake in shares of Eastman Chemical by 119.7% during the 1st quarter. Cetera Advisors LLC now owns 10,088 shares of the basic materials company’s stock worth $1,011,000 after acquiring an additional 5,496 shares in the last quarter. Institutional investors and hedge funds own 83.65% of the company’s stock. Eastman Chemical Company Profile ( Get Free Report ) Eastman Chemical Company operates as a specialty materials company in the United States, China, and internationally. The company's Additives & Functional Products segment offers amine derivative-based building blocks, intermediates for surfactants, metam-based soil fumigants, and organic acid-based solutions; specialty coalescent and solvents, paint additives, and specialty polymers; and heat transfer and aviation fluids. See Also Receive News & Ratings for Eastman Chemical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eastman Chemical and related companies with MarketBeat.com's FREE daily email newsletter .How Trump’s bet on voters electing him managed to silence some of his legal woes(Reuters) - Companies ranging from finance majors to Silicon Valley behemoths are pledging donations to Donald Trump's inaugural fund as business leaders rush to ensure a favorable relationship with the U.S. president-elect after his November election win. Trump is set to take office in January and executives are hoping a positive rapport with his administration, such as the one Tesla boss Elon Musk has established, could mean notable benefits for their companies. Below is a list of companies that are contributing funds for Trump's inauguration for his second term in the White House. ROBINHOOD MARKETS Retail trading platform Robinhood Markets donated $2 million, a company spokesperson said. UBER TECHNOLOGIES Uber Technologies and its CEO Dara Khosrowshahi donated $1 million each, a company spokesperson told Reuters. AMAZON.COM Amazon is donating $1 million. The company will also air the inauguration event on its Prime Video service, an Amazon spokesperson said. META PLATFORMS Meta Platforms has donated $1 million, a company spokesperson told Reuters. OPENAI CEO Sam Altman is planning to make a personal donation of $1 million to the inaugural fund, an OpenAI spokesperson confirmed. "President Trump will lead our country into the age of AI, and I am eager to support his efforts to ensure America stays ahead," Altman said in a statement. BANK OF AMERICA AND GOLDMAN SACHS Bank of America, the second-largest U.S. lender, and investment bank Goldman Sachs plan to contribute to Trump's inaugural committees, but have yet to decide on the amount, spokespersons for each bank said. (Reporting by Jaspreet Singh, Deborah Sophia, Harshita Mary Varghese and Rishi Kant in Bengaluru; Editing by Pooja Desai)Empowered Funds LLC Purchases 14,070 Shares of The E.W. Scripps Company (NASDAQ:SSP)
Oak Street Health, EmblemHealth, Vytalize Health, and several large national health plans recognize Thyme Care's patient-centric navigation and deep provider relationships as a leading value-based model that delivers on the promise of better care at lower costs Thyme Care generates savings and improves the cancer experience, fueling its national expansion across Medicare Advantage, commercial health plans, employers, provider groups, and CMS's Enhancing Oncology Model Thyme Care Oncology Partners (TCOP) doubles the number of oncologists in its network since launching in March; more than 850 oncologists represented from every major managed service organization now part of the platform NASHVILLE, Tenn. , Dec. 17, 2024 /PRNewswire/ -- Thyme Care today announced new strategic partnerships across the cancer care continuum, enabling the company to achieve 4x year-over-year growth in 2025. With this momentum, Thyme Care expects to bring comprehensive cancer care support services to over 40,000 people with cancer. The cancer care system is nearing a financial and logistical breaking point, strained by systemic inefficiencies and gaps in care that burden patients, providers, and payers alike. Patients and caregivers struggle to navigate a complex and siloed healthcare ecosystem, and often experience barriers to care once they leave the physician's office. Oncologists, regardless of whether they practice in the community or a hospital setting, are not incentivized in the current fee-for-service environment to provide value-based care. These challenges inflate costs for everyone in the care continuum, bringing the entire system closer to a breaking point. Thyme Care addresses challenges by empowering oncologists with the resources to deliver value-based care while providing patients with comprehensive support to navigate their journey in collaboration with their care team. "Thyme Care is the connective tissue between oncologists, primary care providers, hospitals, and health plans, creating a cohesive cancer care delivery system that reduces barriers to care and eases the burden of a cancer diagnosis for everyone involved," said Thyme Care President and Chief Operating Officer Brad Diephuis , MD. "Our partners recognize Thyme Care has the technology, data, and relationships to reduce barriers to care and drive better outcomes and affordability across the system." Thyme Care's 2024 strategic partnerships and key milestones include: Health Plan Partnerships: EmblemHealth , one of New York's largest not-for-profit health insurers, has partnered with Thyme Care to provide comprehensive cancer support for its three million members across the tri-state area. Nearly 30% of EmblemHealth's members with cancer receive care in trusted settings like New York Cancer and Blood Specialists (NYCBS), a Thyme Care Oncology Partner. In addition, several large national plans will be launching with Thyme Care in Q1 of 2025. Primary Care Collaborations: Oak Street Health and Vytalize Health , two leading risk-bearing primary care groups, have chosen Thyme Care as their oncology partner to enhance their specialty offerings for members, aligning value-based primary care and oncology care. These collaborations streamline patient referrals, improve patient care coordination, and reduce unnecessary drug spend. Oncologist Enablement: Thyme Care has rapidly grown its oncology provider relationships to embrace new economic incentives, participate in shared savings models, and deliver patient-centered care beyond its four walls. Since launching its oncology partner platform in March, Thyme Care has more than doubled its oncologist partnerships, now counting more than 850 oncologists across the nation. Northwest Cancer Centers and Oncology Consultants have recently joined the platform. Thyme Care's partnership with American Oncology Network (AON) to support its 3,200+ patients in CMS's Enhancing Oncology Model (EOM) has resulted in $2.5M projected savings across pharmacy interventions over a six-month period. Patient Reach: With the addition of new strategic partnerships, Thyme Care expects to quadruple the number of covered lives across the nation, reaching over 40,000 people with cancer in 2025. By aligning incentives across payers, providers, and patients, Thyme Care reduces barriers to care and streamlines a collaborative, value-based framework that prioritizes better outcomes and affordability. The partnership momentum coincides with other successes this year, including the company's recent $95M Series C raise , the establishment of its scientific advisory board , and the addition of new executive hires including Lalan Wilfong , M.D , senior vice president of value-based care, who joined the company from McKesson/The US Oncology Network. Partner Quotes "Vytalize Health's partnership with Thyme Care represents an exciting step forward in our approach to partnering with preferred oncologists to deliver superior care while also lowering patient cost share. Thyme Care offers specialized expertise in value-based cancer care as well as a nimble and flexible approach to engaging providers and patients," said Vytalize Health Vice President of Network Innovation, Jessica Riccardo . "We are committed to improving health outcomes and affordability for EmblemHealth members, and partnering with Thyme Care is a reflection of our shared vision to deliver value-based care. Thyme Care's innovative model ensures our members receive the guidance and support they need, whether that's in the clinic, at the hospital, or at home," said EmblemHealth Senior Vice President of Medical Management & Chief Health Equity Officer, Abdou Bah . "Our partnership with Thyme Care has been instrumental in helping us succeed in the Enhancing Oncology Model (EOM). Over the past year, Thyme Care's Care Team has worked seamlessly with our oncologists and clinic staff to improve the patient experience, while their insights and analytics have helped us better understand the meaningful savings we're generating. Thyme Care supports our ability to deliver high-quality, value-based care that meets the demands of alternative payment models," said American Oncology Network Chief Medical Officer, Stephen "Fred" Divers, MD. About Thyme Care Thyme Care is the leading value-based care enabler, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. The company partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes, and reduced total cost of care. Thyme Care's approach combines a technology-enabled Care Team and seamless integration with more than 800 oncologists in Thyme Care Oncology Partners, creating a hybrid collaborative care model that guides and supports the entire patient journey. Thyme Care empowers oncologists nationwide through purpose-built tech, advanced data analytics, and virtual patient engagement, driving better care and outcomes in value-based arrangements. Thyme Care is a founding member of CancerX , and is backed by leading investors . To learn more about how Thyme Care is enabling the shift to value-based care in oncology, visit www.thymecare.com . Contact Kimberly Dreisinger Thyme Care Communications [email protected] SOURCE Thyme Care